Berry Genomics' subsidiary's third-generation gene sequencer Sequel®II CNDx has obtained a medical device registration certificate

Berry Genomics' wholly-owned subsidiary, Hangzhou Berry Health Gene Diagnostic Technology Co., Ltd., has recently obtained the medical device registration certificate from the National Medical Products Administration for its third-generation gene sequencer Sequel® II CNDx. This is the world's first third-generation gene sequencing platform approved for clinical application, capable of accelerating sample processing and reporting cycles, thereby improving in-hospital service quality. Berry Genomics has achieved independent production of third-generation sequencing supporting detection reagents, promoting domestic technological achievements to advance globally